NCT06180954View on ClinicalTrials.gov

A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

9

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

November 6, 2020

Study Completion Date

November 6, 2020

Conditions

Healthy

Interventions

DRUG

[14C]-LOXO-305

Administered orally

DRUG

LOXO-305

Administered orally

DRUG

[14C]-LOXO-305

Administered IV

Trial Locations (1)

53704

Covance Clinical Research Unit, Madison

Sponsors

Collaborators (1)

Loxo Oncology, Inc.

All Listed Sponsors

collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY